105 related articles for article (PubMed ID: 32825973)
1. Node negative colorectal cancer patients: assesment of high-risk features on recurrence.
van der Linden RLA; Rijstenberg LL; van der Linden JC; Vogelaar FJ; Nagtegaal ID; Pruijt JFM; van de Velde CJH; van den Brule A; Bosscha K
Pathol Res Pract; 2020 Sep; 216(9):153034. PubMed ID: 32825973
[TBL] [Abstract][Full Text] [Related]
2. MSI status is associated with distinct clinicopathological features in BRAF mutation colorectal cancer: A systematic review and meta-analysis.
Wu M; Kim YS; Ryu HS; Choi SC; Kim KY; Park WC; Kim MS; Myung JY; Choi HS; Kim EJ; Lee MY
Pathol Res Pract; 2020 Jan; 216(1):152791. PubMed ID: 31866097
[TBL] [Abstract][Full Text] [Related]
3. Node-negative colon cancer: histological, molecular, and stromal features predicting disease recurrence.
Strous MTA; van der Linden RLA; Gubbels ALHM; Faes TKE; Bosscha K; Bronkhorst CM; Janssen-Heijnen MLG; de Bruïne AP; Vogelaar FJ
Mol Med; 2023 Jun; 29(1):77. PubMed ID: 37344790
[TBL] [Abstract][Full Text] [Related]
4. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases.
Fujiyoshi K; Yamamoto G; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
Oncol Rep; 2017 Feb; 37(2):785-792. PubMed ID: 28000889
[TBL] [Abstract][Full Text] [Related]
5. Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer.
Ooki A; Akagi K; Yatsuoka T; Asayama M; Hara H; Takahashi A; Kakuta M; Nishimura Y; Yamaguchi K
J Surg Oncol; 2014 Dec; 110(8):982-8. PubMed ID: 25154726
[TBL] [Abstract][Full Text] [Related]
6. The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage.
Bläker H; Alwers E; Arnold A; Herpel E; Tagscherer KE; Roth W; Jansen L; Walter V; Kloor M; Chang-Claude J; Brenner H; Hoffmeister M
Clin Gastroenterol Hepatol; 2019 Feb; 17(3):455-462.e6. PubMed ID: 29660527
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
[TBL] [Abstract][Full Text] [Related]
9. Genomic Profiling of Stage II Colorectal Cancer Identifies Candidate Genes Associated with Recurrence-Free Survival, Tumor Location, and Differentiation Grade.
Dimberg J; Andersson RE; Haglund S
Oncology; 2020; 98(8):575-582. PubMed ID: 32408300
[TBL] [Abstract][Full Text] [Related]
10. Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer.
Osumi H; Shinozaki E; Wakatsuki T; Suenaga M; Ichimura T; Ogura M; Takahari D; Ooki A; Suzuki T; Ota Y; Nakayama I; Chin K; Miki Y; Yamaguchi K
Int J Cancer; 2019 Nov; 145(9):2488-2495. PubMed ID: 30963570
[TBL] [Abstract][Full Text] [Related]
11. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.
Murcia O; Juárez M; Rodríguez-Soler M; Hernández-Illán E; Giner-Calabuig M; Alustiza M; Egoavil C; Castillejo A; Alenda C; Barberá V; Mangas-Sanjuan C; Yuste A; Bujanda L; Clofent J; Andreu M; Castells A; Llor X; Zapater P; Jover R
PLoS One; 2018; 13(9):e0203051. PubMed ID: 30188916
[TBL] [Abstract][Full Text] [Related]
12. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
13. The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.
Chouhan H; Sammour T; Thomas ML; Moore JW
J Surg Oncol; 2018 Dec; 118(8):1311-1317. PubMed ID: 30399198
[TBL] [Abstract][Full Text] [Related]
14. Mutation Spectra of Common Cancer-Associated Genes in Different Phenotypes of Colorectal Carcinoma Without Distant Metastasis.
Chang SC; Lin PC; Lin JK; Lin CH; Yang SH; Liang WY; Chen WS; Jiang JK
Ann Surg Oncol; 2016 Mar; 23(3):849-55. PubMed ID: 26471487
[TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients.
Won DD; Lee JI; Lee IK; Oh ST; Jung ES; Lee SH
BMC Cancer; 2017 Jun; 17(1):403. PubMed ID: 28583095
[TBL] [Abstract][Full Text] [Related]
16. Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor.
Fujiyoshi K; Yamamoto G; Takenoya T; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
Anticancer Res; 2017 Jan; 37(1):239-247. PubMed ID: 28011498
[TBL] [Abstract][Full Text] [Related]
17. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
[TBL] [Abstract][Full Text] [Related]
18. Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer.
Zlobec I; Kovac M; Erzberger P; Molinari F; Bihl MP; Rufle A; Foerster A; Frattini M; Terracciano L; Heinimann K; Lugli A
Int J Cancer; 2010 Dec; 127(11):2569-75. PubMed ID: 20162668
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
[TBL] [Abstract][Full Text] [Related]
20. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
Sehdev A; Cramer HM; Ibrahim AA; Younger AE; O'Neil BH
Discov Med; 2016 May; 21(117):341-7. PubMed ID: 27355330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
